DE69320469D1 - Behandlung von herpesvirus infektion - Google Patents

Behandlung von herpesvirus infektion

Info

Publication number
DE69320469D1
DE69320469D1 DE69320469T DE69320469T DE69320469D1 DE 69320469 D1 DE69320469 D1 DE 69320469D1 DE 69320469 T DE69320469 T DE 69320469T DE 69320469 T DE69320469 T DE 69320469T DE 69320469 D1 DE69320469 D1 DE 69320469D1
Authority
DE
Germany
Prior art keywords
treatment
herpesvirus infection
herpesviruses
oligopeptide
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69320469T
Other languages
English (en)
Inventor
Michael Twist
Richard W Barnett
Martin Summer-Smith
Lorne Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allelix Biopharmaceuticals Inc
Original Assignee
Allelix Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharmaceuticals Inc filed Critical Allelix Biopharmaceuticals Inc
Application granted granted Critical
Publication of DE69320469D1 publication Critical patent/DE69320469D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69320469T 1992-04-23 1993-04-21 Behandlung von herpesvirus infektion Expired - Lifetime DE69320469D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87239892A 1992-04-23 1992-04-23
PCT/CA1993/000166 WO1993021941A1 (en) 1992-04-23 1993-04-21 Treatment of herpesvirus infection

Publications (1)

Publication Number Publication Date
DE69320469D1 true DE69320469D1 (de) 1998-09-24

Family

ID=25359492

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69320469T Expired - Lifetime DE69320469D1 (de) 1992-04-23 1993-04-21 Behandlung von herpesvirus infektion

Country Status (7)

Country Link
EP (1) EP0637247B1 (de)
JP (1) JPH08501060A (de)
AT (1) ATE169822T1 (de)
AU (1) AU4037793A (de)
CA (1) CA2134119A1 (de)
DE (1) DE69320469D1 (de)
WO (1) WO1993021941A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
CA2152373C (en) * 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
DE19520792A1 (de) * 1995-06-07 1996-12-12 Bloch Wilhelm Dr Verwendung der Stickstoffmonoxidsynthese hemmenden Substanzen der Gruppe der L-Argininanaloge zur Herstellung eines Mittels zur Abschwellung entzündlich bzw. allergisch angeschwollener Nasenschleimhaut und der Hemmung entzündlich und allergisch bedingter Nasensekretion
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
EP1656945A1 (de) * 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmazeutische Zusammensetzung enthaltend Oligoarginin
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
MXPA02001857A (es) 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
BR122019000258B1 (pt) * 2007-07-26 2021-09-14 Revance Therapeutics, Inc Composição farmacêutica ou cosmética compreendendo um peptídeo catiônico e kit para administração da mesma
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins
AU660947B2 (en) * 1990-10-24 1995-07-13 Allelix Biopharmaceuticals Inc. Peptide-based inhibitors of HIV replication

Also Published As

Publication number Publication date
WO1993021941A1 (en) 1993-11-11
ATE169822T1 (de) 1998-09-15
CA2134119A1 (en) 1993-11-11
EP0637247A1 (de) 1995-02-08
AU4037793A (en) 1993-11-29
JPH08501060A (ja) 1996-02-06
EP0637247B1 (de) 1998-08-19

Similar Documents

Publication Publication Date Title
GR3022838T3 (en) Peptide-based inhibitors of hiv replication
DE69320469D1 (de) Behandlung von herpesvirus infektion
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
DK0973735T3 (da) Polyaromatiske antivirale præparater
DE69131200T2 (de) Herpes simplex virus vp16 impfstoffe
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
DE69330268D1 (de) Hämoregulierende peptide
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DE69125262D1 (de) Synergische Mischung zur Behandlung von Herpes
DE69608959T2 (de) Chlamydia impfstoffen
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
DE69514928D1 (de) Gegen protozoen wirksamezyklische tetrapeptide
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ES2073286T3 (es) Productos cosmeticos estables.
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
DE69231465T2 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ES2062266T3 (es) Uso de quinolil- e isoquinoliloxazol-2-onas para la obtencion de un medicamento destinado para la prevencion de infecciones por virus envueltos por glicoproteinas.
ES2068739A1 (es) Inhibidores retrovirables de proteasas.
HUP9904189A2 (hu) Eténtartalmú oldatok fertőzések elleni terápiás és profilaktikus alkalmazásra
RU93046287A (ru) Аминодиольные ингибиторы протеза

Legal Events

Date Code Title Description
8332 No legal effect for de